Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics Inc (NQ: VRDN )

14.88 -0.09 (-0.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 412,034
Open 15.12
Bid (Size) 14.85 (3)
Ask (Size) 14.88 (41)
Prev. Close 14.97
Today's Range 14.70 - 15.30
52wk Range 10.93 - 24.18
Shares Outstanding 9,587,155
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Decoding 6 Analyst Evaluations For Viridian Therapeutics
Via Benzinga
VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024
VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-33.42%
-33.42%
1 Month
-13.94%
-13.94%
3 Month
+22.07%
+22.07%
6 Month
-24.12%
-24.12%
1 Year
-20.00%
-20.00%

More News

Read More
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Expert Ratings For Viridian Therapeutics
Via Benzinga
7 Analysts Assess Viridian Therapeutics: What You Need To Know
Via Benzinga
Unveiling 4 Analyst Insights On Viridian Therapeutics
Via Benzinga
Top 3 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Via Investor's Business Daily
3 Small-Cap Stocks With Explosive 2X Growth Potential
Via InvestorPlace
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
From Viridian Therapeutics, Inc.
Via Business Wire
VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
Via InvestorPlace
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.